Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Abeona Therapeutics (ABEO)
NASDAQ:ABEO
Holding ABEO?
Track your performance easily
ABEO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.05 - $9.01
Previous Close$5.52
Volume399.20K
Average Volume (3M)399.72K
Market Cap
$238.88M
Enterprise Value$139.34M
Total Cash (Recent Filing)$122.71M
Total Debt (Recent Filing)$23.16M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
Nov 11, 2024EPS Estimate
-$0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.54
Shares Outstanding43,314,397
10 Day Avg. Volume303,292
30 Day Avg. Volume399,719
Standard Deviation0.27
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)3.03
Price to Sales (P/S)63.36
Price to Cash Flow (P/CF)-4.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit73.53
Enterprise Value/Ebitda-7.40
Forecast
1Y Price Target
$18.00Price Target Upside226.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Abeona Therapeutics News
Ownership Overview
35.31% Insiders
3.09% Mutual Funds
55.17% Other Institutional Investors
6.44% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ABEO FAQ
What was Abeona Therapeutics’s price range in the past 12 months?
Abeona Therapeutics lowest stock price was $3.05 and its highest was $9.01 in the past 12 months.
What is Abeona Therapeutics’s market cap?
Currently, no data Available
When is Abeona Therapeutics’s upcoming earnings report date?
Abeona Therapeutics’s upcoming earnings report date is Nov 11, 2024 which is in 79 days.
How were Abeona Therapeutics’s earnings last quarter?
Abeona Therapeutics released its earnings results on Aug 12, 2024. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.342 by $0.082.
Is Abeona Therapeutics overvalued?
According to Wall Street analysts Abeona Therapeutics’s price is currently Undervalued.
Does Abeona Therapeutics pay dividends?
Abeona Therapeutics does not currently pay dividends.
What is Abeona Therapeutics’s EPS estimate?
Abeona Therapeutics’s EPS estimate is -$0.38.
How many shares outstanding does Abeona Therapeutics have?
Abeona Therapeutics has 43,314,396 shares outstanding.
What happened to Abeona Therapeutics’s price movement after its last earnings report?
Abeona Therapeutics reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.342. Following the earnings report the stock price went up 11.991%.
Which hedge fund is a major shareholder of Abeona Therapeutics?
Among the largest hedge funds holding Abeona Therapeutics’s share is Western Standard Llc. It holds Abeona Therapeutics’s shares valued at 7M.
---
Abeona Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$18.00 (226.38% Upside)
$18.00 (226.38% Upside)
Blogger Sentiment
Bullish
ABEO Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 225.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $233.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 9.9%
Last 30 Days ▼ 9.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
35.80%
12-Months-Change
Fundamentals
Return on Equity
-127.38%
Trailing 12-Months
Asset Growth
150.24%
Trailing 12-Months
Company Description
Abeona Therapeutics
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
---
ABEO Earnings Call
Q2 2024
0:00 / 0:00
---
ABEO Stock 12 Month Forecast
Average Price Target
$18.00
▲(226.38% Upside)
Technical Analysis
Best Analysts Covering ABEO
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+9.72%
reiterated a buy rating 10 days ago
Copying Dae Gon Ha's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +9.72% per trade.
---